Immunological aspects of Alzheimer's disease: Therapeutic implications

BioDrugs

Volumn 15, Issue 5, 2001, Pages 325-337

  Hoozemans, Jeroen J M ^a   Rozemuller, Annemieke J M ^b   Veerhuis, Robert ^a   Eikelenboom, Piet ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; AUTACOID; CYTOKINE; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPASE A2; PROSTAGLANDIN SYNTHASE; SUPEROXIDE; TRANSFORMING GROWTH FACTOR BETA1;

ALZHEIMER DISEASE; AMNESIA; ANTIGEN ANTIBODY COMPLEX; ANTIGEN SPECIFICITY; ANTIINFLAMMATORY ACTIVITY; COGNITION; DISEASE PREDISPOSITION; EPIDEMIOLOGICAL DATA; GENETIC POLYMORPHISM; GLIA CELL; IMMUNIZATION; INFLAMMATION; MICROGLIA; NEUROFIBRILLARY TANGLE; NEUROTOXICITY; PLAQUE FORMING CELL; POSITIVE FEEDBACK; PRIORITY JOURNAL; REVIEW; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; HUMANS;

EID: 0034937842     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200115050-00004     Document Type: Review

References (110)

1. Amyloid beta-protein precursor: New clues to the genesis of Alzheimer's disease
2. Neuropathological diagnosis of Alzheimer's disease: A perspective from longitudinal clinicopathological studies
3. A4 protein in Alzheimer's disease: Primary and secondary cellular events in extracellular amyloid deposition
4. Beta-protein amyloid is widely distributed in the central nervous system of patients with Alzheimer's disease
5. Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease
6. Cerebral amyloidosis, ageing and Alzheimer's disease; a contribution from studies on Down's syndrome
7. Inflammation and Alzheimer's disease
8. Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study
9. Microglial cells around amyloid plaques in Alzheimer's disease express leucocyte adhesion molecules of the LFA-1 family
10. Inflammatory mechanisms in Alzheimer's disease
11. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies
12. Activation of the classical complement pathway in brain tissue of Alzheimer patients
13. Complement activation by beta-amyloid in Alzheimer disease
14. Aggregation state-dependent activation of the classical complement pathway by the amyloid beta peptide
15. Complement C1-inhibitor expression in Alzheimer's disease
16. Interleukin-1 expression in different plaque types in Alzheimer's disease: Significance in plaque evolution
17. Interleukin-6 and alpha-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices
18. Elevated circulating tumor necrosis factor levels in Alzheimer's disease
19. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients
20. Cerebrospinal fluid interleukin-1 beta (IL-1 beta) in Alzheimer's disease and neurological disorders
21. Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia
22. The role of interleukin 1 in acute neurodegeneration and stroke: Pathophysiological and therapeutic implications
23. Amyloidogenic role of cytokine TGF-beta1 in transgenic mice and in Alzheimer's disease
24. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease
25. The role of the acute-phase protein alpha 1-antichymotrypsin in brain dysfunction and injury
26. Apolipoprotein B immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in senile dementia of Alzheimer type
27. Microglia in degenerative neurological disease
28. An important role of heparan sulfate proteoglycan (Perlecan) in a model system for the deposition and persistence of fibrillar A beta-amyloid in rat brain
29. Immunohistochemical identification of heparan sulphate proteoglycan in secondary systemic amyloidosis
30. Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells
31. TNFalpha plus IFNgamma induce the production of Alzheimer beta-amyloid peptides and decrease the secretion of APPs
32. Distribution of beta amyloid associated proteins in plaques in Alzheimer's disease and in the non-demented elderly
33. Complement component C1q modulates the phagocytosis of A beta by microglia
34. Lipopolysaccharide-induced microglial activation in culture: Temporal profiles of morphological change and release of cytokines and nitric oxide
35. Cytokines associated with amyloid plaques in Alzheimer's disease brain stimulate human glial and neuronal cell cultures to secrete early complement proteins, but not C1-inhibitor
36. Activation of macrophages by Alzheimer beta amyloid peptide
37. Acute phase proteins but not activated microglial cells are present in parenchymal beta/A4 deposits in the brains of patients with hereditary cerebral hemorrhage with amyloidosis-Dutch type
38. Microglia in diffuse plaques in hereditary cerebral hemorrhage with amyloidosis (Dutch). An immunohistochemical study
39. Inflammation and Alzheimer's disease: Relationships between pathogenic mechanisms and clinical expression
40. Acute phase proteins are present in amorphous plaques in the cerebral but not in the cerebellar cortex of patients with Alzheimer's disease
41. Up-regulated production and activation of the complement system in Alzheimer's disease brain
42. Accumulation of intercellular adhesion molecule-1 in senile plaques in brain tissue of patients with Alzheimer's disease
43. The cellular basis of delirium and its relevance to age-related disorders including Alzheimer's disease
44. The role of the immune system in neurodegenerative disorders
45. Pathological and biochemical consequences of acute and chronic neuroinflammation within the basal forebrain cholinergic system of rats
46. The cytotoxicity of chronic neuroinflammation upon basal forebrain cholinergic neurons of rats can be attenuated by glutamatergic antagonism or cyclooxygenase-2 inhibition
47. Prostaglandins stimulate calcium-dependent glutamate release in astrocytes
48. Microglia, amyloid and dementia in alzheimer disease. A correlative study
49. Cyclooxygenase-1 in human Alzheimer and control brain: Quantitative analysis of expression by microglia and CA3 hippocampal neurons
50. Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease
51. Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs
52. Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain
53. Association between an interleukin-6 promoter and 3 flanking region haplotype and reduced Alzheimer's disease risk in a German population
54. Genetic polymorphisms in the cathepsin D and interleukin-6 genes and the risk of Alzheimer's disease
55. Association of an interleukin 1 alpha polymorphism with Alzheimer's disease
56. Association of interleukin-1 gene polymorphisms with Alzheimer's disease
57. Association of early-onset Alzheimer's disease with an interleukin-1 alpha gene polymorphism
58. Gene polymorphism affecting alpha1-antichymotrypsin and interleukin-1 plasma levels increases Alzheimer's disease risk
59. Alpha-2 macroglobulin is genetically associated with Alzheimer disease
60. No association between the alpha2-macroglobulin (A2M) deletion and Alzheimer's disease, and no change in A2M mRNA, protein, or protein expression
61. The alpha2-macroglobulin gene in AD: A population-based study and meta-analysis
62. Association of APOE promoter but not A2M polymorphisms with risk of developing Alzheimer's disease
63. Association between polymorphism in regulatory region of gene encoding tumour necrosis factor alpha and risk of Alzheimers disease and vascular dementia: A case control study
64. Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: Interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor receptors I and II, and alpha1-antichymotrypsin
65. Unchanged levels of interleukins, neopterin, interferon-gamma and tumor necrosis factor-alpha in cerebrospinal fluid of patients with dementia of the Alzheimer type
66. Interleukin-6 (IL-6) and soluble forms of IL-6 receptors are not altered in cerebrospinal fluid of Alzheimer's disease patients
67. Rheumatoid arthritis and senile dementia of the Alzheimer's type
68. Anti-inflammatory drugs and Alzheimer disease
69. Inverse association of anti-inflammatory treatments and Alzheimer's disease: Initial results of a co-twin control study
70. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam Study
71. Inflammatory processes and antiinflammatory drugs in Alzheimer's disease: A current appraisal
72. Nonsteroidal anti-inflammatory drugs and Alzheimers: Update on recent data and their therapeutical implications
73. NSAIDs and incident Alzheimer's disease. The Rotterdam Study
74. NSAID and the risk of Alzheimers disease and vascular dementia. The Rotterdam study
75. Interleukin-1 beta induces cyclooxygenase-2 and prostaglandin E(2) synthesis in human neuroblastoma cells: Involvement of p38 mitogen-activated protein kinase and nuclear factor-kappaB
76. Interleukin-1beta induced cyclooxygenase 2 expression and prostaglandin E2 secretion by human neuroblastoma cells: Implications for Alzheimer's disease
77. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease
78. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs
79. Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-gamma in Alzheimer's disease brains
80. Cyclopentenone prostaglandins suppress activation of microglia: Down-regulation of inducible nitric-oxide synthase by 15-deoxy-Delta12,14-prostaglandin J2
81. Role of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) and its natural ligand 15-deoxy-Delta12, 14-prostaglandin J2 in the regulation of microglial functions
82. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation
83. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines
84. Inflammatory mechanisms in Alzheimer's disease: Inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists
85. Cytosolic phospholipase A2 is induced in reactive glia following different forms of neurodegeneration
86. Cytosolic phospholipase A2 (cPLA2) immunoreactivity is elevated in Alzheimer's disease brain
87. Interleukin-1 enhances the ATP-evoked release of arachidonic acid from mouse astrocytes
88. NSAIDS inhibit the IL-1 beta-induced IL-6 release from human post-mortem astrocytes: The involvement of prostaglandin E2
89. Prostaglandin E2 induces interleukin-6 synthesis in human astrocytoma cells
90. Prostaglandin E2 stimulates amyloid precursor protein gene expression: Inhibition by immunosuppressants
91. Prostaglandin E2 induced polymerization of human alpha-1-antichymotrypsin and suppressed its protease inhibitory activity: Implications for Alzheimer's disease
92. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse
93. Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease
94. The lack of accumulation of senile plaques or amyloid burden in Alzheimer's disease suggests a dynamic balance between amyloid deposition and resolution
95. Phagocytosis and deposition of vascular beta-amyloid in rat brains injected with Alzheimer beta-amyloid
96. Estrogen enhances uptake of amyloid beta-protein by microglia derived from the human cortex
97. High affinity binding of monoclonal antibodies to the sequential epitope EFRH of beta-amyloid peptide is essential for modulation of fibrillar aggregation
98. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
99. Antibody clears senile plaques
100. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease
101. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
102. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease
103. Strategies for inhibition of complement activation in the treatment of neurodegenerative diseases
104. Charge-based binding of complement component C1q to the Alzheimer amyloid beta-peptide
105. Neuronal protection in stroke by an sLex-glycosylated complement inhibitory protein
106. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study
107. Propentofylline in the treatment of Alzheimers disease and vascular dementia: A review of phase III trials
108. Clinical trial of indomethacin in Alzheimer's disease
109. Results of a double-blind, placebo-controlled study of celecoxib in the treatment of progression of Alzheimer's disease